{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:18:53Z","timestamp":1783523933529,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1038\/sj.bjc.6601485","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T18:31:12Z","timestamp":1073413872000},"page":"36-40","source":"Crossref","is-referenced-by-count":50,"title":["Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer"],"prefix":"10.1038","volume":"90","author":[{"given":"S","family":"Gori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Colozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Basurto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bisacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V De","family":"Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Crin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,1,6]]},"reference":[{"key":"BF6601485_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","volume":"14","author":"J Baselga","year":"1996","unstructured":"Baselga J, Tripathy D, Mendelson J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu overexpressing metastatic breast cancer. J Clin Oncol 14: 737\u2013744","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR2","first-page":"31","volume":"64","author":"HA Burris III","year":"2000","unstructured":"Burris III HA, Hainswoth JD, Mirand FT (2000) Phase II trial on Herceptin induction followed by combination therapy with paclitaxel and carboplatin: a Minnie Pearl Research Network Trial. Breast Cancer Res Treat 64: 31 (abstract 24)","journal-title":"Breast Cancer Res Treat"},{"key":"BF6601485_CR3","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","volume":"19","author":"HJ Burstein","year":"2001","unstructured":"Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnel CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP (2001) Clinical activity of trastuzumab and vinorelbine in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722\u20132730","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR4","first-page":"19a","volume":"21","author":"X Carbonell","year":"2002","unstructured":"Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Baselga J (2002) Efficacy and safety of 3-weekly Hereceptin in women with HER2-positive metastatic breast cancer: preliminary data from a phase II study. Proc Am Soc Clin Oncol 21: 19a (abstract 73)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601485_CR5","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast cancer. J Clin Oncol 17: 2639\u20132648","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.2002.07.058","volume":"20","author":"FJ Esteva","year":"2002","unstructured":"Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Ewsameli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800\u20131808","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR7","first-page":"96","volume":"26","author":"MS Ewer","year":"1999","unstructured":"Ewer MS, Gibbs HR, Swafford J, Benjamin RS (1999) Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26: 96\u2013101","journal-title":"Semin Oncol"},{"key":"BF6601485_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1023\/A:1013184301155","volume":"12","author":"G Fountzilas","year":"2001","unstructured":"Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, Christodoulou CH, Timotheadou E, Kalofonos CH, Kosmidis P, Adamou A, Papakostas P, Gogas H, Stathopoulos G, Razis E, Bafaloukos D, Skarlos D (2001) Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. Ann Oncol 12: 1545\u20131551","journal-title":"Ann Oncol"},{"key":"BF6601485_CR9","first-page":"69a","volume":"20","author":"K Gelmon","year":"2001","unstructured":"Gelmon K, Arold A, Verma S, Ayoub J, Hemmins F, Leyland-Jones B (2001) Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer. Proc Am Soc Clin Oncol 20: 69a (abstract 271)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601485_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457\u2013481","journal-title":"J Am Statist Assoc"},{"key":"BF6601485_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95: 1592\u20131600","journal-title":"Cancer"},{"key":"BF6601485_CR12","first-page":"302","volume":"69","author":"EE Lower","year":"2001","unstructured":"Lower EE, Blau R, Bismayer J, Brennan L, Broun R, Danneman W, Drosick DR, Hawley DK (2001) Increased brain metastasis detected in metastatic breast cancer patients receiving herceptin. Breast Cancer Treat Res 69: 302 (abstract 521)","journal-title":"Breast Cancer Treat Res"},{"key":"BF6601485_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BF6601485_CR14","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","volume":"18","author":"BC Pestalozzi","year":"2000","unstructured":"Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18: 2349\u20132351","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR15","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","volume":"16","author":"MD Pegram","year":"1998","unstructured":"Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monocloncal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659\u20132671","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0378-1119(94)00866-Q","volume":"159","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. A review. Gene 159: 19\u201327","journal-title":"Gene"},{"key":"BF6601485_CR17","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","volume":"19","author":"AD Seidman","year":"2001","unstructured":"Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theoudolou M, Moynahan ME, Moasser M, Sklarin N, Dicler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587\u20132595","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"AD Seidman","year":"2002","unstructured":"Seidman AD, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol 20: 1215\u20131221","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"D Slamon","year":"2001","unstructured":"Slamon D, Leyland-Jones B, Shak S, Fuchus H, Paton V, Bajamonde A, Fleming T, Eierman W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783\u2013792","journal-title":"N Engl J Med"},{"key":"BF6601485_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer:correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235: 177\u2013182","journal-title":"Science"},{"key":"BF6601485_CR21","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1200\/JCO.2002.20.5.1156","volume":"20","author":"J Speyer","year":"2002","unstructured":"Speyer J (2002) Cardiac dysfunction in the trastuzumab clinical experience. J Clin Oncol 20: 1156\u20131157","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR22","first-page":"55a","volume":"21","author":"M Theodoulou","year":"2002","unstructured":"Theodoulou M, Campos SM, Batist G, Winer E, Norton L, Hudis C, Welles L (2002) TLCD99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ANC); final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21: 55a (abstract 216)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601485_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh M, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon D, Murphy M, Novotny W, Burchmore M, Shak S, Stewart S, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719\u2013726","journal-title":"J Clin Oncol"},{"key":"BF6601485_CR24","first-page":"581","volume":"2","author":"D Yu","year":"1998","unstructured":"Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC (1998) Overexpressing of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell Biol 2: 581\u2013591","journal-title":"Mol Cell Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601485","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:54:47Z","timestamp":1684414487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["BF6601485"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601485","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}